K-975|cas:2563855-03-6|西域试剂

K-975,98.55%

产品编号：Bellancom-138565| CAS NO：2563855-03-6| 分子式：C₁₆H₁₄ClNO₂| 分子量：287.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-138565	￥2000.00	杭州北京（现货）
Bellancom-138565	￥3200.00	杭州北京（现货）
Bellancom-138565	￥6400.00	杭州北京（现货）
Bellancom-138565	￥9000.00	杭州北京（现货）
Bellancom-138565	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

K-975

产品介绍

K-975 是一种有效的，具有选择性和口服活性的 TEAD 抑制剂，可强烈抑制 YAP1/TAZ 和 TEAD 之间的蛋白质-蛋白质相互作用。K-975 通过丙烯酰胺结构与位于 TEAD 棕榈酸酯结合口袋中的 Cys359 共价结合。 K-975 具有抗恶性胸膜间皮瘤的活性。

生物活性

K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma.

体外研究

K-975 (0.1-10000 nM; 144 h) inhibits the cell proliferation of NF2-non-expressing malignant pleural mesothelioma (MPM) cell lines.
K-975 (10-10000 nM; 24 h) inhibits protein-protein interaction (PPI) between Halo-YAP and endogenous TEAD1/4 and Halo-TAZ and TEAD1/4 in NCI-H226 cells.
K-975 (0.1-10000 nM; 24 h) strongly inhibits the reporter activity in NCI-H661/CTGF-Luc cells, with the maximum inhibition of ~70%, and does not inhibit the reporter activity in NCI-H661/NRF2-Luc cells.
K-975 (1-10000 nM; 24 h) decreases the expressions of CTGF, IGFBP3, and NPPB mRNAs, and increases the expression of FBXO32 mRNA in NCI-H226 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	NF2-non-expressing MPM and NF2-expressing malignant MPM cells
Concentration:	0.1, 1, 10, 100, 1000, 10000 nM
Incubation Time:	144 hours
Result:	Had a stronger inhibitory effect against NF2-non-expressing cell lines than NF2-expressing cell lines. Inhibited the proliferation of MSTO-211H cells, an NF2-expressing cell line.

Western Blot Analysis

Cell Line:	NCI-H226 cells
Concentration:	10, 100, 1000, 10000 nM
Incubation Time:	24 hours
Result:	Inhibited TEAD1-YAP1 PPI and TEAD4-YAP1 PPI. Inhibited TEAD1-TAZ PPI and TEAD4-TAZ PPI.

体内研究
(In Vivo)

K-975 (10-300 mg/kg; p.o. twice a day for 14 days) inhibits the tumor growth by inhibiting YAP1/TAZ-TEAD signaling in MPM xenograft mouse models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SCID mice (5 weeks) injected with NCI-H226 or MSTO-211H cells
Dosage:	10, 30, 100, 300 mg/kg
Administration:	P.o. twice a day for 14 days
Result:	Exhibited strong anti-tumor effect in MPM s.c. xenograft mouse models. Decreased the expressions of CTGF, IGFBP3, and NPPB, and increased the expression of FBXO32 in the NCI-H226 xenograft model.

体内研究

K-975 (10-300 mg/kg; p.o. twice a day for 14 days) inhibits the tumor growth by inhibiting YAP1/TAZ-TEAD signaling in MPM xenograft mouse models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SCID mice (5 weeks) injected with NCI-H226 or MSTO-211H cells
Dosage:	10, 30, 100, 300 mg/kg
Administration:	P.o. twice a day for 14 days
Result:	Exhibited strong anti-tumor effect in MPM s.c. xenograft mouse models. Decreased the expressions of CTGF, IGFBP3, and NPPB, and increased the expression of FBXO32 in the NCI-H226 xenograft model.

体内研究

K-975 (10-300 mg/kg; p.o. twice a day for 14 days) inhibits the tumor growth by inhibiting YAP1/TAZ-TEAD signaling in MPM xenograft mouse models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SCID mice (5 weeks) injected with NCI-H226 or MSTO-211H cells
Dosage:	10, 30, 100, 300 mg/kg
Administration:	P.o. twice a day for 14 days
Result:	Exhibited strong anti-tumor effect in MPM s.c. xenograft mouse models. Decreased the expressions of CTGF, IGFBP3, and NPPB, and increased the expression of FBXO32 in the NCI-H226 xenograft model.

性状

Solid

溶解性数据

In Vitro:

DMSO : 220 mg/mL (764.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4754 mL	17.3768 mL	34.7536 mL
5 mM	0.6951 mL	3.4754 mL	6.9507 mL
10 mM	0.3475 mL	1.7377 mL	3.4754 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 5.5 mg/mL (19.11 mM); Suspended solution; Need ultrasonic

此方案可获得 5.5 mg/mL (19.11 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 55.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 5.5 mg/mL (19.11 mM); Clear solution

此方案可获得 ≥ 5.5 mg/mL (19.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 55.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 5.5 mg/mL (19.11 mM); Clear solution

此方案可获得 ≥ 5.5 mg/mL (19.11 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 55.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。